Trial Profile

CD24Fc Administration to Decrease LDL and Inflammation in HIV Patients, Both as Markers of Efficacy and Cardiovascular Risk Reduction (CALIBER)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 14 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Efprezimod alfa (Primary) ; Antiretrovirals
Indications Dyslipidaemias
Focus Adverse reactions; Therapeutic Use
Acronyms CALIBER
Sponsors OncoImmune

Most Recent Events

22 Jun 2021 Status changed from active, no longer recruiting to discontinued due to business reasons.
20 Apr 2021 Protocol amended to add safety parameters as primary endpoints in the study protocol.
20 Apr 2021 Planned End Date changed from 31 Oct 2023 to 4 Oct 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com